Richard S. Levy - 01 Jul 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Jul 2025
Net transactions value
$0
Form type
4
Filing time
03 Jul 2025, 16:39:40 UTC
Previous filing
02 Jul 2025
Next filing
14 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Levy Richard S Director 23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM /s/ Madelyn Zeylikman, Attorney-in-Fact 03 Jul 2025 0001454983

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +1,101 +6.3% 18,474 01 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Award $0 +1,101 $0.000000 1,101 01 Jul 2025 Class A Ordinary Shares 1,101 Direct F1, F2
transaction KNSA Restricted Share Units Options Exercise $0 -1,101 -100% $0.000000 0 01 Jul 2025 Class A Ordinary Shares 1,101 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vested immediately upon grant on July 1, 2025; there was no expiration date for the RSUs.